Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis
With
Genentech, Inc.
Tanox
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female adult patients, body weight between 40-150 kg aged 18-65 years (inclusive)
Patients diagnosed with asthma with Forced Expiratory Volume (FEV1) ≥65% of the predicted normal value for the patient
Positive skin prick test to a specific allergen
Patients had to demonstrate a Provocative Dose 20% FEV1 decline (PD20) response to an aeroallergen in the graded allergen bronchoprovocation testing (ABP) at screening
You may not be if
Current active smokers
Patients who have been hospitalized or had emergency treatment for an asthma attack in the 12 months prior to study start
History of bleeding disorders
History of drug allergy
Pregnant women or nursing mothers
Females of childbearing potential, regardless of whether or not sexually active, if they are not using a reliable form of contraception (surgical contraception or double barrier methods (to be continued for at least two months following last dose) are acceptable).
Sexually active males who have not been sterilized and are not using a condom
History of immunocompromise, including a positive HIV
A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.
History of drug or alcohol abuse within 12 months of study start
Clareo Health | A Study of Efficacy of New Doses of Xolair to Protect From Allergen Challenge in Groups of Asthma Patients Defined by IgE Levels
